U.S. Markets open in 43 mins
  • S&P Futures

    4,117.25
    -29.00 (-0.70%)
     
  • Dow Futures

    34,043.00
    -140.00 (-0.41%)
     
  • Nasdaq Futures

    13,181.25
    -164.75 (-1.23%)
     
  • Russell 2000 Futures

    2,172.30
    -31.00 (-1.41%)
     
  • Crude Oil

    66.05
    +0.77 (+1.18%)
     
  • Gold

    1,832.10
    -4.00 (-0.22%)
     
  • Silver

    27.43
    -0.23 (-0.84%)
     
  • EUR/USD

    1.2117
    -0.0035 (-0.2908%)
     
  • 10-Yr Bond

    1.6420
    +0.0180 (+1.11%)
     
  • Vix

    23.50
    +3.84 (+19.53%)
     
  • GBP/USD

    1.4124
    -0.0020 (-0.1426%)
     
  • USD/JPY

    109.0420
    +0.4220 (+0.3885%)
     
  • BTC-USD

    56,465.55
    +1,097.62 (+1.98%)
     
  • CMC Crypto 200

    1,529.83
    +1,287.15 (+530.39%)
     
  • FTSE 100

    6,967.19
    +19.20 (+0.28%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

Kite Pharma Leads IBB’s Mid-Caps on Its Zuma-1 Phase 1 Results

Peter Neil

IBB Falls as Biotechs Bear the Weight of Global Pressures

(Continued from Prior Part)

IBB’s mid-caps under pressure

The mid-cap (middle capitalization) stocks of the iShares Nasdaq Biotechnology ETF (IBB) fell as much as 2.6% on December 7, 2015, underperforming the SPDR S&P 500 ETF (SPY) and the IBB, which returned -0.6% and -2.3%, respectively.

Among the 30 mid-cap stocks that IBB holds in its portfolio, 27 ended up in the red, while three gave positive returns on the day. IBB’s mid-cap stocks account for ~19.1% of its portfolio. Top mid-cap performers included Kite Pharma (KITE) and Qiagen (QGEN), which returned 1.2% and 0.4%, respectively. Bottom mid-cap performers included Alnylam Pharmaceuticals (ALNY) and Novavax (NVAX), which returned -10.3% and -7.5%, respectively.

The above graph reflects the performances of IBB’s mid-caps, IBB, and SPY. Since the beginning of December 2015, IBB’s mid-caps have returned -3.8%, IBB has returned -2.9%, and SPY has returned -0.1%.

Kite Pharma presents Phase 1 results from Zuma-1

Kite Pharma rose by 1.2% on positive data from its Phase 1 clinical trial of Zuma-1. As per its press release, KITE announced “clinical biomarker data and product characteristics for anti-CD19 chimeric antigen receptor (or CAR) T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma (or NHL) enrolled in an ongoing phase 1-2 clinical trial at the National Cancer Institute (or NCI), which is being conducted under a Cooperative Research and Development Agreement (or CRADA) between Kite and the NCI. In this clinical trial, patients with a range of B cell cancers were conditioned with cyclophosphamide and fludarabine prior to receiving anti-CD19 CAR T cell therapy.”

The results were announced at the 57th American Society of Hematology annual meeting in Orlando, Florida.

KITE closed at $71.26 on December 7, 2015, and was trading above its 100-day moving average but below its 20-day moving average. KITE has a book value of $8.24 per share. With its current price, the stock is being traded at a price-to-book value of 8.65x. KITE has a weight of ~0.6% in IBB’s portfolio.

Continue to Next Part

Browse this series on Market Realist: